Expanding its oncology pipeline, Roche has acquired T-regulatory (Treg) cell specialist, Tusk Therapeutics, in a deal worth potentially up to €655 M (US$766 M). The acquisition gives Roche control of an anti-CD25 antibody that showed in early stage research that could turn off the immunosuppressive effects of regulatory T cells without inhibiting effector cell responses, thus supporting the control of solid tumours. As a result of the deal, Black Belt Therapeutics, a newly formed spin-out, will continue development of the remaining products of Tusk’s portfolio.